Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

3.780 -0.240 (-5.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
Where Revance Therapeutics Stands With Analysts
Via Benzinga
Earnings Preview: Revance Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Analyst Expectations for Revance Therapeutics's Future
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Earnings Preview For Revance Therapeutics
Via Benzinga
7 Analysts Have This to Say About Revance Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
3 Very Oversold Biotech Stocks to Buy Right Now
These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong. 
Via InvestorPlace
3 Very Oversold Pharma Stocks to Buy Right Now
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. 
Via InvestorPlace
Revance to Host Investor Day on September 19, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
The company sells a cosmetic treatment. Now, it's bridging into neuroscience. 
Via Investor's Business Daily
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy. 
Via InvestorPlace
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
7 Stocks to Buy for the Massive Rally Ahead
With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally. 
Via InvestorPlace
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. 
Via MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.